background: cystatin c (cys c) has been implicated as a prognostic marker in cardiovascular disease. the aim of this study was to evaluate the value of cys c as a marker of acute kidney injury (aki) in acute heart failure (ahf), the impact of cys c and n-terminal probrain natriuretic peptides (nt-probnp) on in-hospital and 12 months mortality were also investigated. materials and methods: a tot...

With the discovery that the heart is an endocrine organ, we now know that the heart produces and releases hormones, including the natriuretic peptides (NPs). NPs are thought to be produced and released mainly in response to mechanical stretching, due to increased intravascular volume or under pathophysiological conditions, especially in heart failure (HF). B-type NP (BNP) molecular forms, espec...

BACKGROUND The heterogeneity of circulating peptides may influence the interpretation of results from N-terminal profragment of BNP (NT-proBNP) assays. Our objective was to characterize the heterogeneity for better usability of the assays. METHODS Endogenous proBNP was purified from patient samples and treated with trifluoromethanesulfonic acid (chemical deglycosylation). The human proBNP gen...

BACKGROUND The specific forms of pro-B-type natriuretic peptide (proBNP) that occur in human blood are not yet clear. We demonstrated the presence of several proBNP forms in human plasma with a new affinity chromatography method that can be used in combination with nano-liquid chromatography electrospray ionization tandem mass spectrometry (nano-LC-ESI-MS/MS). METHODS For affinity chromatogra...

Plasma concentrations of B-type na-triuretic peptide (BNP), a 32-amino acid peptide hormone secreted by the myocardium, increase in response to myocardial stretch or strain (1, 2). On secretion, proBNP, the storage form of BNP, is cleaved into the inactive N-terminal proBNP (NT-proBNP) and the endocrinologi-cally active BNP. In patients with heart failure, plasma BNP concentrations are related ...

BACKGROUND The value of routine aminoterminal pro type B natriuretic peptide (NT-proBNP) measurements in outpatient clinics remains unknown. OBJECTIVES We sought to determine the accuracy with which heart failure (HF) specialists can predict NT-proBNP levels in HF outpatients based on clinical assessment. METHODS We prospectively studied 160 consecutive HF patients followed in an outpatient...

Recent studies have shown that not only plasma B-type natriuretic peptide (BNP)-32, but also plasma proBNP-108 is increased in heart failure (HF), and that the current BNP-32 assay kit crossreacts with proBNP-108. It also was shown that both BNP-32 and proBNP-108 were higher in HF than in normal. The proBNP-108/total BNP (BNP-32 + proBNP-108) ratio was widely distributed and patients with HF wi...

INTRODUCTION The plasma N-terminal probrain natriuretic peptide (NT-proBNP) level is an important diagnostic and prognostic marker of heart failure. Recent studies have suggested urinary NT-proBNP as a new and simple test for diagnosis of heart failure. We aim to compare diagnostic value of plasma, fresh and frozen urine levels of N-terminal probrain natriuretic peptide (NT-proBNP) for detectin...